Harrow, Inc..
HROW.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Harrow, Inc. is a pharmaceutical company focused on the development, manufacturing, and commercialization of ophthalmic pharmaceutical products. The company primarily serves the United States market, offering a portfolio of branded and generic medications used in various ophthalmic surgical procedur...Show More
Better Health for All
30
Harrow demonstrates a commitment to improving access to eyecare medications, aligning with the 'Better Health for All' value. The company has launched several initiatives aimed at increasing affordability and accessibility of its products, including VEVYE and other key medications. Harrow's participation in the 340B Prime Vendor Program provides discounted medications to eligible hospitals, potentially benefiting vulnerable populations
1
. The "Harrow Cares" program, in partnership with Cencora, offers commercial copay assistance, patient assistance options, and $0 copay options
2
. The VEVYE Access for All program offers VEVYE at $59 per bottle, including refills, for Klarity-C patients
3
. Additionally, Harrow has partnered with GoodRx to provide discounted pricing on select products
4
,
5
. These programs demonstrate a proactive approach to addressing price accessibility and vulnerable reach, with the goal of improving patient outcomes and overall quality of life
6
. Given the materiality assessment, which indicates a strong alignment between Harrow's core business and the 'Better Health for All' value, these initiatives support a positive score. However, more quantitative data on the actual impact of these programs on vulnerable populations would be needed to justify a higher score.
Fair Money & Economic Opportunity
0
No evidence available to assess Harrow, Inc. on Fair Money & Economic Opportunity.
Fair Pay & Worker Respect
0
The company's overall employee rating on Glassdoor is 3.5 out of 5 stars, based on 18 reviews.
1
This indicates an employee satisfaction level of 70%.
Fair Trade & Ethical Sourcing
0
No evidence available to assess Harrow, Inc. on Fair Trade & Ethical Sourcing.
Honest & Fair Business
0
No evidence available to assess Harrow, Inc. on Honest & Fair Business.
Kind to Animals
-40
Harrow, Inc. is initiating one non-clinical animal study for its MELT-300 tablet to support data needed for a New Drug Application (NDA) submission, which is estimated for the first half of 2027.
1
This indicates that the company conducts animal testing, likely due to legal mandates for regulatory approval, and suggests a policy where legal mandates override alternatives. The company has not disclosed a comprehensive no-testing policy or specific animal testing volumes beyond this planned study.
2
No War, No Weapons
0
Harrow, Inc. is described as a North American ophthalmic pharmaceutical company focused on eyecare solutions.
1
The provided articles consistently state that no data is available regarding defense contracts, dual-use technology, sales to embargoed regimes, peacebuilding investments, conflict divestment policies, or any other metrics related to war or weapons.
2
The company's core business activities, as described, do not involve arms manufacturing, military contracts, or conflict facilitation. Therefore, all applicable KPIs are scored as N/A, indicating no involvement in defense or arms-related activities.
Planet-Friendly Business
0
No evidence available to assess Harrow, Inc. on Planet-Friendly Business.
Respect for Cultures & Communities
0
No specific, concrete data points were found in the provided articles regarding Harrow, Inc.'s performance on any of the KPIs related to Respect for Cultures & Communities.
1
Therefore, no KPIs can be scored.
Safe & Smart Tech
-40
Harrow, Inc. experienced a cybersecurity incident in November 2024 involving unauthorized access to an employee's email account.
1
The company is investigating and has notified federal law enforcement, which aligns with a minor breach.
2
All employees receive annual information security training.
3
The company's privacy policy outlines user rights under the California Consumer Privacy Act (CCPA) to request disclosure and deletion of personal data, but the article also states that data is retained for various legal and operational purposes, including transactions, services, contracts, security, debugging, internal use, and legal obligations, without specifying retention periods or strict minimization practices.
4
The company explicitly states adherence to CCPA.
5
Harrow has a risk-based cybersecurity program, overseen by the CEO and Director of IT, which includes a layered approach to assess, identify, evaluate, and manage risks, incorporating third-party assessments and internal simulations.
6
A Security Incident Response Team is in place, and the Audit Committee receives regular updates on the cybersecurity program.
7
Zero Waste & Sustainable Products
-20
In 2023, Harrow, Inc. achieved a recycling rate of 68.5% for its total pharmaceutical waste.
1
The company reported 100% compliance with hazardous waste disposal.
2
Furthermore, Harrow, Inc. had zero critical regulatory violations in 2024, indicating no waste disposal violations for that year.
3